Fulcrum Therapeutics (FULC) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free FULC Stock Alerts $7.55 -0.25 (-3.21%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 7:18 AM | americanbankingnews.comCantor Fitzgerald Begins Coverage on Fulcrum Therapeutics (NASDAQ:FULC)May 20 at 7:17 AM | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Research Coverage Started at Cantor FitzgeraldCantor Fitzgerald initiated coverage on Fulcrum Therapeutics in a report on Monday. They set an "overweight" rating and a $23.00 target price for the company.May 17 at 2:42 AM | americanbankingnews.comQ2 2024 EPS Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Boosted by Leerink PartnrsMay 17 at 2:10 AM | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) to Post Q2 2024 Earnings of ($0.43) Per Share, HC Wainwright ForecastsMay 16, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug ProspectsMay 16, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Expected to Earn Q2 2024 Earnings of ($0.43) Per ShareFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2024 earnings estimates for Fulcrum Therapeutics in a research report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.4May 16, 2024 | americanbankingnews.comFulcrum Therapeutics (NASDAQ:FULC) Stock Rating Reaffirmed by HC WainwrightMay 16, 2024 | americanbankingnews.comHC Wainwright Comments on Fulcrum Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:FULC)May 16, 2024 | americanbankingnews.comOppenheimer Trims Fulcrum Therapeutics (NASDAQ:FULC) Target Price to $14.00May 15, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Trading 7.5% Higher Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.5%May 15, 2024 | marketbeat.comFulcrum Therapeutics, Inc. to Post FY2028 Earnings of $0.51 Per Share, HC Wainwright Forecasts (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Investment analysts at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. HC Wainwright analyst A. Fein now expMay 15, 2024 | americanbankingnews.comThe Goldman Sachs Group Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to BuyMay 14, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)May 14, 2024 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call TranscriptMay 14, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 18.6% in AprilFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 3,000,000 shares, an increase of 18.6% from the April 15th total of 2,530,000 shares. Based on an average trading volume of 598,700 shares, the short-interest ratio is presently 5.0 days.May 14, 2024 | finance.yahoo.comWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?May 14, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) PT Lowered to $14.00Oppenheimer reduced their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday.May 14, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Fulcrum Therapeutics in a research report on Tuesday.May 14, 2024 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded by The Goldman Sachs Group to BuyThe Goldman Sachs Group raised Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and set a $15.00 target price for the company in a research report on Monday.May 13, 2024 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | finance.yahoo.comFulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...May 13, 2024 | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | globenewswire.comFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular DystrophyMay 12, 2024 | markets.businessinsider.comHere's what to expect from Fulcrum Therapeutics's earningsMay 11, 2024 | americanbankingnews.comFulcrum Therapeutics (FULC) Scheduled to Post Quarterly Earnings on MondayMay 9, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate in Upcoming May ConferencesMay 8, 2024 | finance.yahoo.comFulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet NeurologyMay 7, 2024 | marketbeat.comFulcrum Therapeutics (FULC) Set to Announce Earnings on MondayFulcrum Therapeutics (NASDAQ:FULC) will be releasing earnings before the market opens on Monday, May 13, Zacks reports.May 6, 2024 | globenewswire.comFulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ETMay 1, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest UpdateFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 2,530,000 shares, a growth of 11.9% from the March 31st total of 2,260,000 shares. Based on an average trading volume of 632,000 shares, the short-interest ratio is currently 4.0 days.May 1, 2024 | finance.yahoo.comEpsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company ExpansionApril 30, 2024 | marketbeat.com256,888 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Bought by abrdn plcabrdn plc purchased a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 256,888 shares of the company's stock, valued at approximately $1,7April 16, 2024 | marketbeat.comShort Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Drops By 5.4%Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 2,260,000 shares, a decrease of 5.4% from the March 15th total of 2,390,000 shares. Based on an average daily volume of 668,800 shares, the short-interest ratio is currently 3.4 days.April 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 9, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Moderate Buy" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating onApril 3, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.6% Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.6%March 28, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy SymposiumMarch 25, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Down 6.2% Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 6.2%March 22, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 20, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down to $10.10Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down to $10.10March 19, 2024 | finance.yahoo.comFULC Apr 2024 9.000 putMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)March 18, 2024 | finanznachrichten.deFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 18, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.6%Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.6%March 18, 2024 | msn.comFulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical OfficerMarch 18, 2024 | globenewswire.comFulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 17, 2024 | marketbeat.comHudson Bay Capital Management LP Buys New Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Hudson Bay Capital Management LP bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 196,488 shares of the company's stock, valued at approxMarch 15, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating oMarch 13, 2024 | tmcnet.comFulcrum Deepens Collaboration with Esri, Recognized as Bronze Partner Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry FULC Media Mentions By Week FULC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.240.42▲Average Medical News Sentiment FULC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼353▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TBPH News Today CRBP News Today PEPG News Today SLRN News Today BMEA News Today LXRX News Today ANNX News Today TRDA News Today ANL News Today HRTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
